MA51295A - Dosage, procédé et traitement d'alpha-synucléinopathies - Google Patents

Dosage, procédé et traitement d'alpha-synucléinopathies

Info

Publication number
MA51295A
MA51295A MA051295A MA51295A MA51295A MA 51295 A MA51295 A MA 51295A MA 051295 A MA051295 A MA 051295A MA 51295 A MA51295 A MA 51295A MA 51295 A MA51295 A MA 51295A
Authority
MA
Morocco
Prior art keywords
synucleinopathies
dosage
alpha
treatment
Prior art date
Application number
MA051295A
Other languages
English (en)
Inventor
Karina Fog
Pekka Kallunki
Ibrahim John Malik
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA51295A publication Critical patent/MA51295A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA051295A 2017-12-21 2018-12-19 Dosage, procédé et traitement d'alpha-synucléinopathies MA51295A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201700738 2017-12-21

Publications (1)

Publication Number Publication Date
MA51295A true MA51295A (fr) 2021-05-05

Family

ID=65011965

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051295A MA51295A (fr) 2017-12-21 2018-12-19 Dosage, procédé et traitement d'alpha-synucléinopathies

Country Status (7)

Country Link
US (1) US20200309796A1 (fr)
EP (1) EP3729088B1 (fr)
JP (2) JP7498663B2 (fr)
CN (1) CN111630382A (fr)
ES (1) ES2898929T3 (fr)
MA (1) MA51295A (fr)
WO (1) WO2019121952A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018109058A1 (fr) 2016-12-16 2018-06-21 H. Lundbeck A/S Agents, utilisations et procédés
KR102573778B1 (ko) 2017-02-17 2023-08-31 브리스톨-마이어스 스큅 컴퍼니 알파-시뉴클레인에 대한 항체 및 그의 용도
CN115032400A (zh) * 2022-03-28 2022-09-09 首都医科大学附属北京天坛医院 α-突触核蛋白在辅助诊断神经退行性疾病中的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1186621A (fr) 1981-08-10 1985-05-07 John L. Hendrix Systeme de dosage immunologique
FR2570703B1 (fr) 1984-09-26 1988-07-08 Commissariat Energie Atomique Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents
AU636562B2 (en) 1986-12-15 1993-05-06 British Technology Group Usa, Inc. Monomeric phthalocyanine reagents
US4876190A (en) 1987-10-21 1989-10-24 Becton Dickinson & Company Peridinin-chlorophyll complex as fluorescent label
FR2624862B1 (fr) 1987-12-18 1990-06-08 Oris Ind Cryptates de terres rares, procedes d'obtention, intermediaires de synthese et application a titre de marqueurs fluorescents
CN101308144A (zh) * 2007-05-16 2008-11-19 首都医科大学宣武医院 检测受试者体液内疾病相关蛋白聚合能力的方法
FR2934684B1 (fr) * 2008-07-31 2012-11-16 Cis Bio Int Methode de detection de l'internalisation de proteines membranaires.
US20110136146A1 (en) 2008-08-04 2011-06-09 Novartis Ag Bioassay for polyq protein
EP2539366B1 (fr) * 2010-02-26 2017-11-08 BioArtic Neuroscience AB Anticorps se liant aux protofibrilles et utilisation associée dans des méthodes thérapeutiques et diagnostiques pour la maladie de parkinson, la démence à corps de lewy et d'autres alpha-synucléinopathies
US20130183696A1 (en) * 2010-09-15 2013-07-18 Constance Neely Wilson Methods of use and kit for measurement of lipopolysaccharide with a time resolved fluorescence based assay
EP2643056A4 (fr) 2010-11-24 2014-06-04 Elan Pharm Inc Activité phagocytaire en tant que marqueur d'une synucléinopathie
CN105917232B (zh) 2013-12-03 2020-10-16 塞尚公司 用于选择性确定胎盘生长因子2的方法
JP6531171B2 (ja) * 2014-06-27 2019-06-12 エックスワイ エバーグリーン テクノロジー カンパニー Ｃｎｓ由来エクソソームを富化するための方法
EP3191599B1 (fr) 2014-09-11 2023-08-02 Board Of Regents Of the University Of Texas System Détection de protéines mal-repliées
DK3341725T3 (da) 2015-08-25 2021-09-06 Prothena Biosciences Ltd Fremgangsmåder til detektering af phosphoryleret alpha-synuklein

Also Published As

Publication number Publication date
WO2019121952A1 (fr) 2019-06-27
JP2021508044A (ja) 2021-02-25
CN111630382A (zh) 2020-09-04
JP2024096748A (ja) 2024-07-17
EP3729088B1 (fr) 2021-10-20
JP7498663B2 (ja) 2024-06-12
EP3729088A1 (fr) 2020-10-28
ES2898929T3 (es) 2022-03-09
US20200309796A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
IL272444A (en) Compounds, their salts and methods for treating diseases
MA42420A (fr) Vaccins pour le traitement et la prévention du cancer
MA43190A (fr) Traitement de la dyslipidémie mixte
DK3277815T3 (da) Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
MA54622A (fr) Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné
DK3153169T3 (da) Fremgangsmåde til behandling af tumor, farmaceutisk sammensætning og medicinæskesæt
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
MA44510A (fr) Methode de traitement du psoriasis avec dosage intervalle augmenté d'anticorps anti-il12 et/ou -23
MA45865A (fr) Procédés de détection et de traitement d'une tumeur exprimant pt346 pdk1
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MA51295A (fr) Dosage, procédé et traitement d'alpha-synucléinopathies
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
FR3039368B1 (fr) Procede de traitement cosmetique
FR3034011B1 (fr) Procede de traitement cosmetique des cheveux
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
MA46347A (fr) Système et procédé de traitement de crevettes
DK3445362T3 (da) Sammensætning og fremgangsmåde til behandling af stofskiftesygdomme
FR3017624B1 (fr) Methode predictive pour caracteriser la radiosensibilite et la reaction tissulaire d'un patient envers un rayonnement ionisant therapeutique
FR3044227B1 (fr) Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires
MA50526A (fr) Cocristaux, compositions pharmaceutiques de ceux-ci, et méthodes de traitement les impliquant
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
MA52921A (fr) Procédé de traitement des cheveux, kit et utilisation du kit
DE112020004659A5 (de) Behandlungsanlage und Behandlungsverfahren
MA43178A (fr) Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci